MAPK1 and melanoma: Considering that mdivi-1 sensitized NRAS-mutant melanoma cells to the action of vemurafenib, and that DRP1 is a downstream target for phosphorylation of active ERK [38], we investigated whether this effect was related to its inhibition of DRP1 phosphorylation and consequent inhibition of mitochondrial fission.